QIAGEN Digital Insights - Business-News-Today.com

🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

Business news, market intelligence, and global industry analysis.

The Latest

Mesoblast (ASX: MSB) clears key treatment milestone ahead of mid-2027 back pain trial readout

Santos (ASX: STO) warns Australia’s 20% gas reservation rule could undermine GLNG economics

Russian missiles strike Kyiv as attacks injure 17 in Zaporizhzhia and Kharkiv

Regis Resources (ASX: RRL) drops Vault Minerals bid, letting Genesis Minerals’s A$5.6bn offer proceed

Representative image of molecular diagnostics, market volatility, and leadership transition themes as Qiagen (NYSE: QGEN) approaches its new CEO appointment and Q1 2026 earnings, with investors closely watching QIAstat-Dx, QuantiFERON, and strategic review developments.

Read More

Healthcare Industry News

Qiagen (NYSE: QGEN) at a crossroads ahead of new CEO and Q1 2026 results

Qiagen (NYSE: QGEN) retail investor roadmap: strategic review, CEO search, 2026 product pipeline and what the May earnings call means for shareholders.

April 3, 2026

web analytics